
Boehringer Ingelheim launches trio of Phase III trials in oncology
Boehringer Ingelheim is expanding its precision oncology footprint by initiating three global Phase III clinical trials, targeting aggressive lung and neuroendocrine cancers. The company aims to integrate biomarker-informed therapies earlier into treatment pathways, seeking to improve long-term outcomes for patients with historically limited options.
:max_bytes(150000):strip_icc():focal(999x0:1001x2)/ted-danson-oceana-081624-tout-e6bc00c561ec488881fa53ab91e7c18d.jpg)






















